Gyeonggi-do, South Korea

Hyeongchan Oh


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hyeongchan Oh: Innovator in Tricyclic Derivative Compounds

Introduction

Hyeongchan Oh is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on tricyclic derivative compounds.

Latest Patents

Hyeongchan Oh holds a patent for a tricyclic derivative compound, which includes a method for preparing the compound and a pharmaceutical composition comprising it. This invention focuses on novel tricyclic derivative compounds, including their optical isomers, racemates, and pharmaceutically acceptable salts. These compounds exhibit excellent activity against PARP-1, tankyrase-1, and tankyrase-2. The compounds are particularly useful in the prevention or treatment of various conditions, including neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, and cancer.

Career Highlights

Hyeongchan Oh is associated with Je Il Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has led to the creation of valuable pharmaceutical compounds that have the potential to improve patient outcomes in several medical areas.

Collaborations

Hyeongchan Oh collaborates with talented individuals in his field, including Hyunho Lee and Kwangwoo Chun. These partnerships enhance the innovative capacity of his research and contribute to the development of effective pharmaceutical solutions.

Conclusion

Hyeongchan Oh's contributions to the field of pharmaceuticals through his patent on tricyclic derivative compounds highlight his role as an influential inventor. His work has the potential to significantly impact the treatment of various diseases and improve the quality of life for many individuals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…